These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36806262)

  • 21. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
    Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
    Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
    Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
    BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Content of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral mucosa and inflamed periodontal tissue.
    Deppe H; Hohlweg-Majert B; Hölzle F; Kesting MR; Wagenpfeil S; Wolff KD; Schmitt M
    Quintessence Int; 2010 Feb; 41(2):165-71. PubMed ID: 20165748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.
    Karamanavi E; Angelopoulou K; Lavrentiadou S; Tsingotjidou A; Abas Z; Taitzoglou I; Vlemmas I; Erdman SE; Poutahidis T
    Transl Oncol; 2014 Apr; 7(2):174-187.e5. PubMed ID: 24913672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration.
    Sisson TH; Nguyen MH; Yu B; Novak ML; Simon RH; Koh TJ
    Blood; 2009 Dec; 114(24):5052-61. PubMed ID: 19812386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
    Ulisse S; Baldini E; Mottolese M; Sentinelli S; Gargiulo P; Valentina B; Sorrenti S; Di Benedetto A; De Antoni E; D'Armiento M
    BMC Cancer; 2010 Apr; 10():151. PubMed ID: 20403162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.
    Gossage JA; Humphries J; Modarai B; Burnand KG; Smith A
    J Vasc Surg; 2006 Nov; 44(5):1085-90. PubMed ID: 17098546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
    Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
    Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
    Qian J; Li B; Yin M; Shen P; Sun K
    Zhonghua Er Ke Za Zhi; 2015 Jun; 53(6):453-8. PubMed ID: 26310557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
    Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC
    J Vasc Surg; 1997 Jan; 25(1):157-64. PubMed ID: 9013920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
    Sood V; Luke CE; Deatrick KB; Baldwin J; Miller EM; Elfline M; Upchurch GR; Wakefield TW; Henke PK
    Thromb Haemost; 2010 Dec; 104(6):1174-83. PubMed ID: 20886179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a novel inhibitor of urokinase-type plasminogen activator.
    Zhu M; Gokhale VM; Szabo L; Munoz RM; Baek H; Bashyam S; Hurley LH; Von Hoff DD; Han H
    Mol Cancer Ther; 2007 Apr; 6(4):1348-56. PubMed ID: 17431113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
    Rantala J; Kemppainen S; Ndode-Ekane XE; Lahtinen L; Bolkvadze T; Gurevicius K; Tanila H; Pitkänen A
    Epilepsy Behav; 2015 Jan; 42():117-28. PubMed ID: 25506794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of stimulation of α7 nicotinic acetylcholine receptors in the suppressive effect of tropisetron on dextran sulfate sodium-induced colitis in mice.
    Tasaka Y; Yasunaga D; Kiyoi T; Tanaka M; Tanaka A; Suemaru K; Araki H
    J Pharmacol Sci; 2015 Mar; 127(3):275-83. PubMed ID: 25837923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotection by urokinase plasminogen activator in the hippocampus.
    Cho E; Lee KJ; Seo JW; Byun CJ; Chung SJ; Suh DC; Carmeliet P; Koh JY; Kim JS; Lee JY
    Neurobiol Dis; 2012 Apr; 46(1):215-24. PubMed ID: 22293605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
    Ji F; Chen YL; Jin EY; Wang WL; Yang ZL; Li YM
    World J Gastroenterol; 2005 Jun; 11(21):3222-6. PubMed ID: 15929171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell associated urokinase activity and colonic epithelial cells in health and disease.
    Gibson PR; van de Pol E; Doe WF
    Gut; 1991 Feb; 32(2):191-5. PubMed ID: 1650741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.